Credit Suisse’s Werewolf Therapeutics HOWL Stock Holding History

Credit Suisse’s Portfolio HOWL Stock Details HOWL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-14	Closed	–	–	4140
2022 Q2	$0	Buy	+14	New	+$64	﹤0.01%	4094

Other funds holding HOWL

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Adage Capital Partners

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Credit Suisse's HOWL Position: Q3 2022 in Review

Credit Suisse sold out of Werewolf Therapeutics (HOWL) in Q3 2022, closing a stake of 14 shares.

Credit Suisse first reported a position in HOWL in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 44 funds tracked by Wall St. Rank hold HOWL as of Q3 2022.

Credit Suisse reported no remaining Werewolf Therapeutics position as of Q3 2022 after selling out during the quarter.
Credit Suisse sold 14 Werewolf Therapeutics shares in Q3 2022.
Credit Suisse first reported a position in Werewolf Therapeutics in Q2 2022 and held it in 1 quarter.
Credit Suisse's Werewolf Therapeutics position peaked at $0 in Q2 2022.
44 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.